Tsvetkov et al. [73] reported that reduced mRNA expression of at least one 19S proteasome component, including PSMD1, PSMD5, PSMD6, or PSMD10, correlated with loss of TNFα/NF-κB signaling in myeloma cells that are resistant to the proteasome inhibitors, MG132, bortezomib, and carfilzomib. Here, PSMD5 is linked to plasma cell myeloma.